Quest Diagnostics Incorporated has announced a new research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital. This collaboration will focus on two clinical trials investigating the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test. The trials aim to evaluate its effectiveness as a tool for postoperative therapy decisions in cases of cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma. Led by Dr. Dan Faden and co-led by Sophia Shalhout, PhD, and Kevin Emerick, MD, the trials will assess Haystack MRD's impact on risk stratification and early detection of residual disease. Results of these studies have not yet been presented and will be available in the future.